Alzheimer disease (AD) is the most common cause of dementia in older adults. The Fagan lab works on a variety of projects researching AD, including the DominantlyInherited Alzheimer Network (DIAN-Obs), DIAN Clinical Trials Unit (DIAN-TU), Alzheimer’s BiomarkersConsortium –Down Syndrome (ABC-DS)and Longitudinal Early-onset Alzheimer’s Disease (LEADS).
Ongoing research focuses primarily on longitudinal changes of CSF biomarkers(including Aβ40, Aβ42, total tau, phosphorylated tau-181, neurofilament light chain, YKL-40, SNAP-25, neurogranin and VILIP-1) during the natural course of the disease. Furthermore, in collaboration with other investigators, fluid biomarker profiles are compared with various clinical, cognitive, imaging, genetic and other measures hypothesized to be involved in AD and/or other neurodegenerative disorders. Biomarker analyses of samples from various clinical trials are used to evaluate target engagement, pathologic outcome variables and/or drug efficacy. Biomarker core efforts also include assay development, standardization and validation.
Anne Fagan’s email:
ATTN: Fagan Lab
Steven & Susan Lipstein BJC Institute of Health (BJCIH), Floor 09
425 S. Euclid Ave.
St. Louis, MO 63110
Lab phone number: